Recombinant Human Taste receptor type 2 member 41 (TAS2R41)

Basic Research Questions

• What is TAS2R41 and what is its primary function in human biology?

  TAS2R41 is a member of the taste 2 receptor (TAS2R) family, which comprises 25 bitter taste receptors in humans. These receptors are G protein-coupled receptors (GPCRs) that mediate bitter taste perception. TAS2R41 specifically functions as a "specialist" receptor with high selectivity for certain bitter compounds. Unlike broadly tuned bitter receptors that recognize numerous compounds, TAS2R41 has a narrow receptive range, recognizing only a few specific agonists . Its primary function is the detection of specific bitter compounds, with current evidence suggesting chloramphenicol as its main known agonist .

• How is TAS2R41 expression distributed throughout human tissues?

  While TAS2R41 was initially identified in taste buds, research has revealed the expression of bitter taste receptors including TAS2R41 in various extraoral tissues. Studies have detected TAS2R41 along the gastrointestinal tract, with varying expression levels in different segments. Research by Jalsˇevac et al. (2024) showed that TAS2R41 consistently exhibits lower expression levels compared to other TAS2Rs (such as TAS2R14) across various gastrointestinal mucosal tissues . This extraoral expression suggests potential roles beyond taste perception, possibly including metabolic regulation and gut-brain axis modulation.

• What are the confirmed agonists for human TAS2R41?

  TAS2R41 has a remarkably narrow agonist profile compared to other bitter taste receptors. The antibiotic chloramphenicol has been identified as its primary agonist through heterologous expression systems and functional assays . Thalmann et al. (2013) were the first to identify this specific interaction. Additionally, there is evidence suggesting that the non-nutritive sweetener sucralose may also activate TAS2R41 at certain concentrations, making it one of the few receptors known to interact with both bitter and sweet-tasting compounds . The highly selective nature of TAS2R41 may indicate specialized roles in detecting specific compounds rather than broad bitter taste detection.

• How does TAS2R41 compare structurally to other bitter taste receptors?

  TAS2R41, like other bitter taste receptors, belongs to the class T2 G protein-coupled receptor family. It contains seven transmembrane domains characteristic of GPCRs. TAS2R receptors, including TAS2R41, exhibit very minor homology with other GPCR families, making structural characterization challenging . Unlike sweet taste receptors (TAS1R family) that function as heterodimers, TAS2R41 functions as a monomeric receptor. The receptor lacks the large extracellular N-terminal domain seen in TAS1R family members . The structural specificity of TAS2R41 likely contributes to its narrow agonist selectivity, although detailed structural analyses through crystallography or cryo-EM have not yet been reported for this specific receptor.

Advanced Research Questions

• What are the current methodologies for functionally characterizing TAS2R41?

  Several complementary methodologies have been developed to study TAS2R41 function:

  • Heterologous Expression Systems: TAS2R41 can be expressed in cell lines such as HEK293S cells using tetracycline-inducible systems for controlled expression .

  • Calcium Imaging Assays: Traditional approaches monitor changes in intracellular calcium levels upon receptor activation, though these can be limited by interference from autofluorescent compounds .

  • Bioluminescence-Based Assays: Recently developed methods offer improved signal windows and reduced interference from autofluorescent matrices. These assays utilize mt-clytin II (a calcium-dependent photoprotein) to monitor receptor activation with greater sensitivity than fluorescence-based methods .

  • BRET-Based Binding Assays: By fusing TAS2R41 to nanoluciferase (Nluc) either at the N- or C-terminus, researchers can develop BRET-based binding assays to directly measure ligand interactions .

  • Tryptophan Fluorescence: Intrinsic tryptophan fluorescence can be used to demonstrate binding of compounds to purified receptors and determine binding affinities .

• How do genetic variations in TAS2R41 affect receptor function and bitter taste perception?

  Genetic variability in TAS2R41 significantly impacts receptor function:

  Genetic Variant	Functional Impact	Reference
  P127L (rs10772420)	~10-fold reduction in response to chloramphenicol	Thalmann et al. (2013)

  These genetic variations explain differential bitter perception of certain compounds among individuals. For example, the P127 variant of TAS2R41 shows significantly higher activation by chloramphenicol compared to the L127 variant . This functional polymorphism may have clinical relevance, as individuals with the more responsive P127 variant might perceive greater bitterness from chloramphenicol-containing medications, potentially affecting medication compliance. Studies have shown that variation in TAS2R genes can predict perceived bitterness of medications, suggesting potential applications in personalized medicine approaches .

• What expression systems are most effective for producing functional recombinant TAS2R41?

  Several expression systems have been utilized for producing functional TAS2R41:

  • Mammalian Cell Lines: HEK293S cells with tetracycline-inducible systems provide controlled expression and appropriate post-translational modifications necessary for receptor function .

  • AD-293 or 293AD Cell Lines: These modified HEK293 cell lines offer stronger adherent properties, facilitating media changes during functional assays .

  • Cell-Free Protein Synthesis (CFPS): The ALiCE® system based on Nicotiana tabacum lysate has been reported for TAS2R41 expression, maintaining the protein production machinery while removing components unnecessary for expression .

  Challenges in expression include low expression levels, potential misfolding, and difficulties in purification. Strategies to improve expression include:

  • Altering N-terminal signal sequences to enhance cell surface expression

  • Co-expression with appropriate G proteins (typically Gα16-gust44)

  • Optimization of detergent conditions for solubilization while maintaining receptor function

• How does human TAS2R41 differ from its mouse ortholog?

  Human TAS2R41 and its mouse ortholog (t2r41_mouse) show several important differences:

  • Sequence Variation: The mouse ortholog (also known as Tas2r41, Tas2r12, Tas2r126, or Tas2r26) has distinct sequence features compared to the human variant .

  • Agonist Profiles: Sequence-orthologous bitter taste receptors between human and mouse have distinct agonist profiles, suggesting divergent evolution of their ligand-binding properties .

  • Receptor Tuning: When compared with humans, mice possess fewer broadly tuned receptors and more narrowly tuned receptors like TAS2R41, supporting the idea that larger receptor repertoires enable the evolution of more specialized receptors .

  • Expression Patterns: Expression levels of mouse Tas2r41 and orthologous receptors have been studied using qRT-PCR and in situ hybridization, showing varying expression across taste cells .

  These differences highlight the importance of species-specific considerations when using mouse models to study bitter taste receptors and extrapolating findings to human taste perception.

• What are the current methods for developing selective TAS2R41 agonists and antagonists?

  Developing selective compounds for TAS2R41 involves several approaches:

  1. Structure-Activity Relationship (SAR) Studies: Analyzing structural features of known agonists like chloramphenicol to identify essential molecular determinants for receptor activation .

  2. Fluorescent Derivatives: Synthesizing fluorescent derivatives of agonists by introducing fluorophores at specific positions (e.g., meta- or para-positions of aromatic rings) with appropriate linkers to maintain bioactivity while enabling binding detection .

  3. Click Chemistry Approaches: Utilizing azide- or alkyne-functionalized dyes (such as TAMRA-5 or TAMRA-6) connected via linkers of varying length and polarity to develop probes for binding studies .

  4. Computational Modeling: Despite challenges due to low homology with other GPCRs, homology modeling and molecular docking can guide rational design of selective ligands .

  5. High-Throughput Screening: Testing diverse compound libraries using bioluminescence-based assays that offer improved signal windows compared to traditional fluorescence-based methods .

• How can CRISPR-Cas9 technology be applied to study TAS2R41 function?

  CRISPR-Cas9 technology offers powerful approaches for studying TAS2R41:

  • Gene Knockout Studies: gRNA sequences designed by the Feng Zhang laboratory specifically target TAS2R41 within the human genome with minimal off-target effects .

  • gRNA Design Considerations: When designing knockout experiments, researchers should consider:

    1. Using at least two gRNA constructs per gene to increase success rates

    2. Confirming gRNA sequences against target gene sequences before ordering

    3. Targeting specific exons or splice variants as needed

  • Delivery Methods: Typically, a sequence-verified plasmid containing all required elements (U6 promoter, spacer sequence, gRNA scaffold, and terminator) is delivered to cells .

  • Functional Validation: Following genetic modification, receptor function can be assessed using calcium mobilization assays, bioluminescence-based assays, or other functional readouts to confirm successful knockout or modification .

  • Phenotypic Analysis: In cellular or animal models, altered bitter taste responses to chloramphenicol can serve as functional validation of successful TAS2R41 modification .

• What are the pharmacological implications of TAS2R41 activation in clinical settings?

  TAS2R41 activation has several potential pharmacological implications:

  • Medication Compliance: Genetic variants in TAS2R41 (particularly P127L) affect bitterness perception of chloramphenicol, potentially influencing patient compliance with antibiotic treatment regimens .

  • Personalized Medicine Approaches: Screening patients for TAS2R41 variants could inform personalized formulation strategies for medications with known bitter tastes .

  • Extraoral Effects: Given the expression of TAS2R41 in gastrointestinal tissues, activation may influence gut hormone secretion and metabolic processes beyond taste perception .

  • Dosage Form Considerations: The impact of TAS2R41 activation on perceived bitterness is particularly relevant for liquid oral formulations rather than tablets or capsules that bypass taste receptors .

  • Potential for Targeted Formulations: Understanding TAS2R41 genetics could enable development of personalized medication formulations based on patient genetic profiles to improve compliance and outcomes .

• What are the current challenges in purifying functional TAS2R41 for structural studies?

  Purification of functional TAS2R41 presents several challenges:

  • Expression Levels: TAS2R41 typically expresses at low levels in heterologous systems, complicating large-scale purification efforts .

  • Detergent Solubilization: Appropriate detergent selection is critical for maintaining receptor structure and function during solubilization from cell membranes .

  • Structural Validation: Circular dichroism (CD) spectroscopy can confirm proper folding with evidence of secondary structures after purification .

  • Functional Assessment: Intrinsic tryptophan fluorescence assays can verify that purified receptors maintain ligand-binding capabilities with physiologically relevant affinities .

  • Stability Issues: Like many GPCRs, TAS2R41 may exhibit limited stability in detergent solutions, requiring optimization of buffer conditions and potentially the use of stabilizing agents or nanodiscs for structural studies .

  Despite these challenges, successful purification of detergent-solubilized TAS2R41 has been reported, with evidence of proper folding and maintained binding ability for compounds like sucralose, neotame, acesulfame-K, and perillartine .